ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2015
Breakthrough cancer pain: a comparison of surveys with European and Canadian patients.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan.Cancer reports (Hoboken, N.J.) · 2019Trial
- Development and preliminary validation of a clinician-administered Chinese-language tool for breakthrough cancer pain assessment.Asia-Pacific journal of oncology nursing · 2026Article
- Cancer pain and quality of life structural equation model based on the biopsychosocial model.BMC cancer · 2025Article
- Scheduled and Breakthrough Opioid Use for Cancer Pain in an Inpatient Setting at a Tertiary Cancer Hospital.Current oncology (Toronto, Ont.) · 2024Article
- Breakthrough and Episodic Cancer Pain from a Palliative Care Perspective.Current oncology (Toronto, Ont.) · 2023Article
- High-rate breakthrough cancer pain and tumour characteristics - literature review and case series.Drugs in context · 2023Review
- Multidisciplinary approach, continuous care and opioid management in cancer pain: case series and review of the literature.Drugs in context · 2023Article
- Relationship between breakthrough cancer pain, background cancer pain and analgesic treatment - case series and review of the literature.Drugs in context · 2022Review
- Patients' Satisfaction with Breakthrough Cancer Pain Therapy: A Secondary Analysis of IOPS-MS Study.Cancer management and research · 2022Article
- Interference with daily functioning by breakthrough pain in patients with cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- Prevalence and characterization of breakthrough pain in patients with cancer in Spain: the CARPE-DIO study.Scientific reports · 2019Observational
- Article
- Practice Patterns in Distinguishing Between Background Pain and Breakthrough Pain During Patient Education: a Korean Physician Survey.Journal of cancer education : the official journal of the American Association for Cancer Education · 2018Article
- Assessment and treatment of breakthrough cancer pain: from theory to clinical practice.Journal of pain research · 2017Review
- Article
- Article
- A Korean Nationwide Survey for Breakthrough Cancer Pain in an Inpatient Setting.Cancer research and treatment · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBreakthrough cancer pain is defined as a transient exacerbation of pain that occurs spontaneously or in response to a trigger, despite stable and controlled background pain. Breakthrough pain often causes significant functional impairments for patients and can decrease quality of life.
objectiveThe objective of the study was to determine differences between breakthrough cancer pain incidence and management in Canada and Europe.
methodsData collected from previous studies of breakthrough cancer pain in Canada and Europe was compared. A standard survey with identical inclusion/exclusion criteria was utilized for both patient populations.
resultsBoth groups of patients had a similar number and duration of breakthrough pain episodes, and similar pain intensity and pain interference with their daily activities. European patients reported better analgesic efficacy and satisfaction with management, and a greater percentage of European patients were prescribed a transmucosal fentanyl formulation (19.1 vs 2.9 %). More European patients (55 %) than Canadian patients (32.5 %) took their rescue medication every time they had a breakthrough pain episode.
conclusionsBreakthrough cancer pain in both Canadian and European patients greatly impacts their daily living, and both groups of patients had similar experiences with breakthrough cancer pain. Currently, this pain is not adequately managed for many patients. The role for new analgesic treatments in management of breakthrough cancer pain needs further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.